tiprankstipranks
Trending News
More News >
LIDDS AB (SE:LIDDS)
:LIDDS

LIDDS AB (LIDDS) AI Stock Analysis

Compare
0 Followers

Top Page

SE

LIDDS AB

(Berlin:LIDDS)

Rating:37Underperform
Price Target:
LIDDS AB's overall stock score is significantly impacted by its weak financial performance due to persistent losses and negative cash flow. Technical analysis further suggests bearish momentum with prices below key moving averages. Valuation concerns arise from a negative P/E ratio and lack of dividend yield, indicating high risk. The company's stability is challenged by the need for improved profitability and operational efficiency.

LIDDS AB (LIDDS) vs. iShares MSCI Sweden ETF (EWD)

LIDDS AB Business Overview & Revenue Model

Company DescriptionLIDDS AB (LIDDS) is a Swedish pharmaceutical company that specializes in the development of innovative drug delivery systems for cancer treatments and other therapeutic areas. The company leverages its proprietary NanoZolid® technology to create injectable, controlled-release formulations that enhance the efficacy and safety profiles of active pharmaceutical ingredients. By focusing on improving drug delivery, LIDDS aims to address unmet medical needs and enhance patient outcomes across various clinical indications.
How the Company Makes MoneyLIDDS AB generates revenue through licensing agreements, collaborations, and partnerships with pharmaceutical companies interested in utilizing its NanoZolid® technology for their drug development projects. The company earns upfront payments, milestone payments, and royalties based on the commercial success of products developed using their technology. Additionally, LIDDS might engage in contract research and development services, offering its expertise in drug formulation and delivery. These strategic alliances and service offerings are crucial for the company's financial performance and growth in the competitive pharmaceutical industry.

LIDDS AB Financial Statement Overview

Summary
LIDDS AB faces significant challenges across its financial statements. The income statement reflects ongoing operational and profitability issues, while the balance sheet remains debt-free but fails to translate into positive returns. Cash flow pressures persist, with negative free cash flow indicating liquidity challenges. The company needs to focus on improving its revenue growth and operational efficiency to enhance its financial health.
Income Statement
20
Very Negative
LIDDS AB has struggled with consistently negative gross and net profit margins over multiple years, indicating ongoing profitability challenges. The revenue growth rate was positive for 2024 due to a very low base in 2023, but overall, the company has not shown sustainable revenue growth. EBIT and EBITDA margins are also negative, further highlighting operational inefficiencies.
Balance Sheet
35
Negative
The company has a strong equity position with no debt, leading to a solid equity ratio. However, the return on equity is negative due to persistent losses, which is a concern. The balance sheet shows stability in terms of equity but highlights the challenge of translating this into profitability.
Cash Flow
25
Negative
Free cash flow remains negative, although the company has managed to reduce its cash flow deficit over the years. The operating cash flow to net income ratio is negative, reflecting cash outflows exceeding net losses. The company has not been able to generate positive free cash flow consistently, which limits its financial flexibility.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue32.00K0.001.89M3.55M345.00K
Gross Profit-3.40M-12.92M-36.62M-37.27M-24.79M
EBITDA-4.49M-39.67M-36.11M-36.81M-32.20M
Net Income-4.31M-40.21M-36.86M-37.27M-32.33M
Balance Sheet
Total Assets8.16M17.66M25.92M55.58M54.20M
Cash, Cash Equivalents and Short-Term Investments5.51M13.51M5.26M34.00M36.07M
Total Debt0.000.003.99M0.000.00
Total Liabilities1.98M3.76M10.57M7.07M11.40M
Stockholders Equity6.18M13.90M15.35M48.51M42.81M
Cash Flow
Free Cash Flow-5.53M-26.50M-36.40M-45.04M-31.17M
Operating Cash Flow-5.43M-26.22M-35.59M-42.64M-27.42M
Investing Cash Flow-94.00K-282.00K-810.00K-2.40M-3.75M
Financing Cash Flow-280.00K34.76M7.66M42.97M59.64M

LIDDS AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.04
Price Trends
50DMA
0.04
Positive
100DMA
0.08
Negative
200DMA
0.10
Negative
Market Momentum
MACD
<0.01
Negative
RSI
62.65
Neutral
STOCH
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LIDDS, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.04, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 62.65 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:LIDDS.

LIDDS AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
50
Neutral
kr5.39B12.66-80.61%5.12%37.36%27.71%
38
Underperform
kr104.81M-105.78%58.72%70.69%
37
Underperform
kr12.96M-107.11%94.98%
32
Underperform
kr7.65M-209.54%97.86%
30
Underperform
kr1.06M-186.04%57.91%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:LIDDS
LIDDS AB
0.10
-0.04
-31.65%
SE:QUIA
QuiaPEG Pharmaceuticals Holding AB
0.01
-0.03
-76.74%
SE:SCOL
Scandion Oncology A/S
0.01
-0.20
-94.34%
SE:SPAGO
Spago Nanomedical AB
0.31
0.02
7.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 29, 2025